{"id":4728,"date":"2025-06-19T23:03:27","date_gmt":"2025-06-19T23:03:27","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/06\/19\/cogent-biosciences-blueprint-medicines-bezuclastinib-readout\/"},"modified":"2025-06-19T23:03:27","modified_gmt":"2025-06-19T23:03:27","slug":"cogent-biosciences-blueprint-medicines-bezuclastinib-readout","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/06\/19\/cogent-biosciences-blueprint-medicines-bezuclastinib-readout\/","title":{"rendered":"STAT+: Cogent Biosciences-Blueprint Medicines tiff turns spicy on eve of immune drug study readout"},"content":{"rendered":"<p>    STAT+: Cogent Biosciences-Blueprint Medicines tiff turns spicy on eve of immune drug study readout<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p><em>This story is an excerpt from Adam\u2019s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up\u00a0<a href=\"https:\/\/www.statnews.com\/signup\/scorecard\/\">here<\/a>\u00a0to get it delivered to their inbox.<\/em><\/p>\n<p>Cogent Biosciences and Blueprint Medicines are direct competitors who hate each other.\u00a0<\/p>\n<p>During a talk at the recent Jefferies Global Healthcare Conference, Cogent CEO Andy Robbins said Blueprint Medicines\u2019 Ayvakit was so toxic that it was killing patients. Only after Blueprint lowered the Ayvakit dose was the drug tolerable enough to be modestly effective.<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/06\/19\/cogent-biosciences-blueprint-medicines-bezuclastinib-readout\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Adam Feuerstein<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/06\/19\/cogent-biosciences-blueprint-medicines-bezuclastinib-readout\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: Cogent Biosciences-Blueprint Medicines tiff turns spicy on eve of immune drug study readout This story is an excerpt from Adam\u2019s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up\u00a0here\u00a0to get it delivered to their inbox. Cogent Biosciences and Blueprint Medicines are direct competitors who hate each other.\u00a0 During a talk at the recent [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3013,2200,2194,2154,2155,2564,2152],"tags":[2150],"class_list":["post-4728","post","type-post","status-publish","format-standard","hentry","category-adams-biotech-scorecard","category-adams-take","category-biotech","category-biotechnology","category-pharmaceuticals","category-rare-disease","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/4728"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=4728"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/4728\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=4728"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=4728"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=4728"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}